Cardiovascular Disease Global Market Till 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

ResearchMoz presents this most up-to-date research on "Cardiovascular Disease Global Market Till 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth".

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as the aforementioned PCSK9 inhibitors and direct factor Xa inhibitors.

Scope

• Analysis of innovation in the CVD market in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include hypertension, dyslipidemia and thrombotic events.
• A brief introduction to CVD, including symptoms, pathophysiology, and an overview of pharmacotherapy for the key diseases.
• Identification of key marketed products, with a focus on historical and forecast sales patterns and an overview of each drug’s mechanism of action.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=869174

• Comprehensive review of the pipeline, analyzed on the basis of stage of development, molecule type and molecular target.
• In-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries and drug patent expirations will influence market value.

Reasons to buy

This report will allow you to 

• Understand the current clinical and commercial landscape through a comprehensive analysis of the innovation in the CVD market in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include hypertension, dyslipidemia and thrombotic events
• Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns and an overview of the drug’s mechanism of action.
• Analyze the CVD pipeline through a comprehensive review of the pipeline, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at CVD clinical trials as to provide an insight into the risk associated with attempting to bring CVD pipeline drugs.
• Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patents expirations will influence market value.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=869174

ResearchMoz | Cardiovascular Disorders Drug Development Pipeline Review, 2017

Researchmoz added Most up-to-date research on "ResearchMoz | Cardiovascular Disorders Drug Development Pipeline Review, 2017" to its huge collection of research reports.

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

There are over 1,200 pipeline products within the CVD therapy area. Over 50% of these products are small molecules however there is also diversification with regards to molecule types within the pipeline. In addition, the molecular targets in the pipeline are considerably diverse with a high frequency of products acting on targets related to lipid metabolism and those which act on elements of the coagulation cascade.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as PCSK9 inhibitors and direct factor Xa inhibitors.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1049123

The report provides comprehensive information on the pipeline development landscape for Hypertension, Dyslipidemia, Venous thromboembolism and Heart failure, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

• Which companies are the most active within the pipeline for CVD.
• Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication.
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies.
• What are the most important R&D milestones and data publications to have happened in this disease area.

Reasons to buy

• Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
• Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
• Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
• Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1049123

Therapeutics Global Market For Cardiovascular Disease 2022 - Sanofi And Novartis To Become Market Leaders As Praluent & Entresto Drive Revenue Growth

ResearchMoz presents this most up-to-date research on "Therapeutics Global Market For Cardiovascular Disease 2022 - Sanofi And Novartis To Become Market Leaders As Praluent & Entresto Drive Revenue Growth".

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

There has been vast scientific innovation within the CVD therapeutics market over recent decades, particularly within the anti-dyslipidemia market with the advent of statins such as Lipitor, the best-selling drug of all time, which produce marked reductions in cholesterol levels. More recently, the commonly used direct factor Xa inhibitors which produce anti-coagulant effects, have been made available for oral administration and the advent of PCSK9 inhibitors provide a viable alternative dyslipidemia treatment for when statins are unsuitable or inefficient. There are currently 1368 pipeline drugs within the cardiovascular disease market, the largest therapy area being thrombosis, with 406 pipeline products indicated for treatment or prevention of thrombotic events.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=869174

Scope

• Analysis of innovation in the CVD market in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include hypertension, dyslipidemia and thrombotic events.
• A brief introduction to CVD, including symptoms, pathophysiology, and an overview of pharmacotherapy for the key diseases.
• Identification of key marketed products, with a focus on historical and forecast sales patterns and an overview of each drug’s mechanism of action.

Reasons to buy

This report will allow you to 

• Understand the current clinical and commercial landscape through a comprehensive analysis of the innovation in the CVD market in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include hypertension, dyslipidemia and thrombotic events
• Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns and an overview of the drug’s mechanism of action.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=869174